1. Evaluation
A legitimate treatment pathway begins with a clinical reason to investigate the growth-hormone axis. The clinician considers history, symptoms, prior diagnoses, medications and relevant risk factors.
2. Testing and context
Depending on the clinical situation, endocrine evaluation may include IGF‑1 and other testing. The correct tests and interpretation depend on the patient and diagnostic question.
3. Prescription
If treatment is appropriate, a clinician selects a treatment plan and prescription. Brand choice may reflect device preference, availability, coverage and medical judgment.
4. Lawful dispensing and storage
The prescribed medication should come through a lawful channel with appropriate product handling. Temperature-sensitive products require attention to manufacturer instructions.
5. Monitoring and follow-up
Follow-up allows reassessment of symptoms, adverse effects, treatment goals and relevant laboratory data. A legitimate treatment plan evolves with clinical information rather than running indefinitely on autopilot.
Frequently asked questions
Is HGH therapy just a medication purchase?
No. Legitimate therapy includes evaluation, prescribing, lawful dispensing and follow-up.
Can brand selection matter?
Yes. Devices, presentations, access and patient preference can differ among branded somatropin products.
Why is follow-up important?
Because treatment response, adverse effects and the continued appropriateness of therapy need reassessment.